Woman's World on MSN

How to boost your thyroid function for more energy and a faster metabolism

An underactive thyroid can trigger everything from weight gain to thinning hair to plummeting energy levels. Fortunately, giving the small, butterfly-shaped gland in the front of the neck some ...

Gordon Fraser Shares New Insights on Triple Lipid Complex Supporting Skin Barrier Function and Moisture Retention

New insights from Gordon Fraser spotlight a Triple Lipid Complex that supports skin barrier function, hydration, and ...

Advanced Smile Dentistry Introduces Free 3D Scan and Consultation for Dental Implant Patients

The practice introduces complementary CBCT-based 3D scans to support accurate dental implant evaluation and treatment ...
IEEE

Direct Construction of Optimal Z-Complementary Code Sets With Even Lengths by Using Generalized Boolean Functions

Abstract: The Z-complementary code set (ZCCS) is well-known for being used in multicarrier code-division multiple access (MC-CDMA) systems to provide interference-free communication in a ...
Opinion
Health AffairsOpinion

Beyond Star Ratings: Proposal For A Medicare Advantage Transparency Scorecard

Transparency Scorecard to increase visibility into non-clinical dimensions of MA plan performance that fall outside the appropriate scope of Star Ratings.
Business Wire

Omeros Announces First Commercial Sales of YARTEMLEA

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
Pharmabiz

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Omeros Corporation, an innovative biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
FiercePharma

Omeros scores its 1st FDA nod as stem cell transplant drug Yartemlea approved

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...
Seeking Alpha

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic ...
MarketWatch

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...